

JAGSONPAL PHARMACEUTICALS LIMITED

Corporate Office: Nimai Tower, 3rd Floor, Plot No. 412-415, Phase-IV, Udyog Vihar, Gurugram -122015, Haryana (India)

October 14, 2024

The Department of Corporate Services - Listing BSE Ltd, Phiroz Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 507789	The Department of Corporate Services - Listing National Stock Exchange of India Ltd., Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 Symbol: JAGSNPHARM
--	---

Subject: Report under Regulation 10(7) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Dear Sir/ Madam,

We herewith forward the report under regulation 10(7) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011 received from Infinity Portfolio Holdings being Promoter and Promoter Group of the company pursuant to the corporatization of shares.

You are requested to take the above on record.

Thank you,
Yours faithfully,

For **Jagsonpal Pharmaceuticals Limited**

Abhishek Joshi
Company Secretary and Compliance Officer

E-25
14-16

Infinity Portfolio Holdings

C/o Apex Fund & Corporate Services (Mauritius)
6th Floor, Two Tribeca, Tribeca Central, Trianon 72261, Mauritius
Tel: +230 404 3900 Fax: +230 454 6824

Date: October 14th 2024

To
The Securities and Exchange Board of India
SEBI Bhawan, Plot no. C4-A, G Block
Bandra Kurla Complex, Bandra (East)
Mumbai, Maharashtra-400051

Re: Report under Regulation 10(7) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 on account of the acquisition of equity shares of Jagsonpal Pharmaceuticals Ltd ("Target Company").

Dear Sir/Madam,

Please find herewith the Report under Regulation 10(7) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011, with regard to the purchase of 2,287,180 equity shares by Infinity Portfolio Holdings:

- (i) 2,200,000 equity shares of Target Company from Infinity Holdings through an on-market transaction; and
- (ii) 87,180 equity shares of Target Company from Infinity Consumer Holdings through an on-market transaction.

The respective intimation and report under Regulation 10(5) and 10(6) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011 have already been filed with BSE Limited and National Stock Exchange of India Limited on 5th September 2024 and 17th September 2024, respectively.

The applicable fees of Rs. 150,000 (One lakh fifty thousand only) plus GST and other charges aggregating to Rs. 177,005.90 have been remitted through RTGS/NEFT vide UTRN KKBKH24285658522 dated October 11th 2024.

Kindly take the same on your record and acknowledge the receipt of the same

Thanking you,

Yours faithfully,

For Infinity Portfolio Holdings



Kooshal Ashley Torul (Director)
Authorized signatory
Place: Mauritius
Date: October 14th 2024



Note: The address for Infinity Portfolio Holdings has changed effective from October 1st 2024.

Format under Regulation 10(7) – Report to SEBI in respect of any acquisition made in reliance upon exemption provided for in regulation 10(1)(a)(iii) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (“SEBI (SAST) Regulations” or “Takeover Regulations”)

1	General Details	
	a.	Name, address, telephone no., e-mail of acquirer(s) {In case there are multiple acquirers, provide full contact details of any one acquirer (the correspondent acquirer) with whom SEBI shall correspond.} Infinity Portfolio Holdings C/o Apex Fund & Corporate Services (Mauritius) Ltd, 6th Floor, Two Tribeca, Tribeca Central, Trianon 72261, Mauritius Email id: infinity-MU@apexgroup.com Contact No: +230 5784 6117
	b.	Whether sender is the acquirer (Y/N) Yes
	c.	If not, whether the sender is duly authorized by the acquirer to act on his behalf in this regard (enclose copy of such authorization) N.A.
	d.	Name, address, Tel no. and e-mail of sender, if sender is not the acquirer N.A.
2	Compliance of Regulation 10(7)	
	a.	Date of report October 14 th 2024
	b.	Whether report has been submitted to SEBI within 21 working days from the date of the acquisition Yes
	c.	Whether the report is accompanied with fees as required under Regulation 10(7) Yes, the applicable fees of Rs. 150,000 (One lakh fifty thousand only) plus GST and other charges aggregating to Rs. 177,005.90 have been remitted through RTGS/NEFT vide UTRN KKBKH24285658522 dated October 11 th 2024. Copy of the same is enclosed herewith as Annexure A.
3	Compliance of Regulation 10(5)	
	a.	Whether the report has been filed with the Stock Exchanges where the shares of the Company are listed, atleast 4 working days before the date of the proposed acquisition. Yes, Copy of the same is enclosed herewith as Annexure B
	b.	Date of Report September 05 th 2024
4	Compliance of Regulation 10(6)	
	a.	Whether the report has been filed with the Stock Exchanges where the shares of the Company are listed within 4 working days of the acquisition Yes, Copy of the same is enclosed herewith as Annexure C
	b.	Date of Report September 16 th 2024 (sent on September 17 th 2024)
5	Details of the Target Company	
	a.	Name & address of TC Jagsonpal Pharmaceuticals Ltd. Registered Office: T 210 J, Shabpur Jat, New Delhi, Delhi-110049

The following abbreviations have been used all through the document: TC stands for ‘Target Company’, ‘Takeover Regulations’ stands for ‘SEBI (Substantial Acquisition of Shares and Takeover Regulations, 2011)’

	b.	Name of the Stock Exchange(s) where the shares of the TC are listed	BSE and NSE			
6	Details of the acquisition					
	a.	Date of acquisition	September 13 th 2024			
	b.	Acquisition price per share (in Rs.)	i) 2,200,000 shares at Rs. 400 per share ii) 87,180 shares at Rs. 406.25 per share			
	c.	Regulation which would have been triggered off, had the report not been filed under Regulation 10(7)(whether Regulation 3(1), 3(2),4 or 5)	Regulation 3(2) and 4			
	d.	Shareholding of acquirer/s and PACs individually in TC (in terms of no: & as a percentage of the total share/voting capital of the TC)(*)	Before the acquisition		After the acquisition	
			No. of Shares	% w.r.t total share capital /voting rights of TC	No. of Shares	% w.r.t total share capital /voting rights of TC
		Name(s) of the acquirer(s)(**)				
		Infinity Portfolio Holdings	-	-	2,287,180	8.6%
		Name(s) of the PACs				
		Infinity Holdings	6,613,020	25.0%	4,413,020	16.7%
		Infinity Consumer Holdings	87,180	0.3%	-	-
		Infinity Holdings Sidecar I	4,755,300	18.0%	4,755,300	18.0%
		Total	11,455,500	43.3%	11,455,500	43.3%
	e.	Shareholding of seller/s in TC (in terms of no: & as a percentage of the total share/voting capital of the TC) (*)	Before the acquisition		After the acquisition	
			No. of Shares	% w.r.t total share capital /voting rights of TC	No. of Shares	% w.r.t total share capital /voting rights of TC
		Name(s) of the seller(s) (**)				
		Infinity Holdings	6,613,020	25.0%	4,413,020	16.7%
		Infinity Consumer Holdings	87,180	0.3%	-	-
		Total	6,700,200	25.3%	4,413,020	16.7%
7	Information specific to the exemption category to which the instant acquisition belongs - Regulation 10(1)(a)(iii)					
	a.	Provide the names of the seller/s	Infinity Holdings and Infinity Consumer Holdings			
	b.	Specify the relationship between the acquirer/s and the seller/s.	In accordance with the (Indian) Companies Act, 2013, (i) Infinity Portfolio Holdings (i.e. the acquirer) is a			

The following abbreviations have been used all through the document: TC stands for 'Target Company', 'Takeover Regulations' stands for 'SEBI (Substantial Acquisition of Shares and Takeover Regulations, 2011)

			subsidiary of Infinity Investment Management; and (ii) Infinity Holdings and Infinity Consumer Holdings (which are both promoters and part of the promoter group of the TC) are also subsidiaries of Infinity Investment Management. Infinity Investment Management holds 100% voting rights in each of Infinity Portfolio Holdings, Infinity Holdings and Infinity Consumer Holdings.
	c.	Confirm that the acquirer and the seller/s satisfy such a relationship as defined in Regulation 10(1)(a)(iii) of the Takeover Regulations	Yes, acquirer and the seller/s satisfy relationship as defined in Regulation 10(1)(a)(iii) of the Takeover Regulations
	d.	If shares of the TC are frequently traded, volume-weighted average market price (VWAP) of such shares for a period of sixty trading days preceding the date of issuance of notice regarding the proposed acquisition to the stock exchanges where the TC is listed.	The volume weighted average market price for a period of 60 trading days preceding the date of issuance of the notice under Regulation 10(5) as traded on the stock exchange where the maximum volume of trading in the shares of the TC are recorded during such period is Rs 365.19 per share.
	e.	If shares of the TC are infrequently traded, the price as determined in terms of clause (e) of sub-regulation (2) of regulation 8.	Not applicable
	f.	Confirm whether the acquisition price per share is not higher by more than twenty-five percent of the price as calculated in (d) or (e) above as applicable.	The shares of TC were acquired at a price not exceeding the limits provided in proviso (i) to Regulation 10(1)(a) of the SEBI (SAST) Regulations
	g.	Date of issuance of notice regarding the proposed acquisition to the stock exchanges where the TC is listed	September 05 th 2024
	h.	Whether the acquirers as well as sellers have complied with the provisions of Chapter V of the Takeover Regulations (corresponding provisions of the repealed Takeover Regulations 1997) (Y/N). If yes, specify applicable regulation/s as well as date on which the requisite disclosures were made along with the copies of the same.	Yes, both acquirer and seller have complied with applicable disclosure requirements in Chapter V of the Takeover Regulations, 2011 (Corresponding provisions of the repealed Takeover Regulations 1997). A Copy of the Disclosure made under Regulation 29(1) and 29(2) and filed on September 17 th 2024, is enclosed herewith as Annexure D
	i.	Declaration by the acquirer that all the conditions specified under regulation 10(1)(a)(iii) with respect to exemptions has been duly complied with.	We hereby declare that all conditions specified under Regulation 10(1)(a)(iii) of SEBI (SAST) Regulations, with respect to exemptions has been complied with.

The following abbreviations have been used all through the document: TC stands for 'Target Company', 'Takeover Regulations' stands for 'SEBI (Substantial Acquisition of Shares and Takeover Regulations, 2011)

We hereby declare that the information provided in the instant report is true and nothing has been concealed there from.

For **Infinity Portfolio Holdings**



Kooshal Ashley Torul (Director)

Authorised signatory

Date: October 14th 2024

Place: Mauritius

NOTE:

(*) In case, percentage of shareholding to the total capital is different from percentage of voting rights, indicate percentage of shareholding and voting rights separately.

(**) Shareholding of each entity shall be shown separately as well as collectively.

The following abbreviations have been used all through the document: TC stands for 'Target Company', 'Takeover Regulations' stands for 'SEBI (Substantial Acquisition of Shares and Takeover Regulations, 2011)

Securities and Exchange Board of
India SEBI(Scan QR Code with QR Reader
to know the transaction status)

NEFT/RTGS Detail

Beneficiary Name: **Securities and Exchange Board of India SEBI Online EFT**

NEFT/RTGS Amount: **177005.90**
(Do not round off amount)

Beneficiary A/C No: **BDSKZEF7GEX02TMKXZ**
(Applicable only for this transaction. First seven characters are alphabets, rest are numbers)

Beneficiary IFSC: **CITI0100000**
(5th character is zero)

Beneficiary Bank: **CITIBANK**
D.N. Road, Fort, Mumbai

Challan Details

Challan Creation Date: 11/10/2024 Recommended transfer within: 2 days of challan creation

I/We (sender) have read, understood and accepted the following terms & conditions:

- 1.I/We will execute NEFT/RTGS from my/our bank within 2 days of creating this slip, post which funds may be refunded and required service may not be rendered.
- 2.Beneficiary Account Number mentioned in this Challan slip is applicable for current transaction only.For any other or new transaction, kindly initiate a new transaction workflow from merchant's website only.
- 3.**NEFT/RTGS should be initiated by using person to person bank account transfer only [R41 mode only].**In case you are requesting your bank branch to initiate NEFT/RTGS on your behalf,it must be specifically using R41 mode only.Using any other mode for transfer of funds will be treated as invalid and required services will not be rendered.
- 4.NEFT/RTGS transfer amount should be an exact match with transaction amount mentioned on this slip (including paisa).Do not round off the transfer amount even for the second decimal place.
- 5.I/We will not initiate multiple NEFT/RTGS by breaking the amount in more than one part. Such EFTs will be treated as invalid transactions and required service will not be delivered.
- 6.NEFT/RTGS should be initiated from the sender's bank account only as any refund/reversal will be credited in the same bank account.
- 7.It is sender's responsibility to ensure that the bank account is enabled for incoming NEFT/RTGS in case of refunds.
- 8.A nominal amount may be charged to the sender towards refund processing for invalid transactions Refunds.

Powered by :



Infinity Portfolio Holdings

C/o Apex Fund & Corporate Services (Mauritius)
Ltd, Lot 15 A3 1st Floor, Cybercity, Ebene 72201, Mauritius
Tel: +230 404 3900 Fax: +230 454 6824

Date: September 05th 2024

To

BSE Limited Phiroz Jeejeebhoy Towers, Dalal Street, Mumbai – 400001	National Stock Exchange of India Ltd., Exchange Plaza, C-1, Block G Bandra Kurla Complex Bandra East Mumbai 400051
--	---

CC: **Jagsonpal Pharmaceuticals Ltd.**

Registered Office:

T 210 J, Shabpur Jat,
New Delhi, Delhi-110049

Dear Sir/ Madam,

Re: Advanced Intimation for proposed purchase of equity shares of Jagsonpal Pharmaceuticals Ltd (“Target Company”) under Regulation 10(5) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

In compliance with the provisions of Regulation 10(1)(a)(iii) read with Regulation 10(5) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011, we wish to submit the disclosure with regard to the proposed purchase of (i) 2,200,000 equity shares of Target Company by Infinity Portfolio Holdings from Infinity Holdings; and (ii) 87,180 equity shares of Target Company by Infinity Portfolio Holdings from Infinity Consumer Holdings, through on-market transactions.

Kindly acknowledge receipt of the same.

Thanking you,

Yours faithfully,

For **Infinity Portfolio Holdings**



Kooshal Ashley Torul (Director)

Authorized signatory

Place: Mauritius

Date: September 05th 2024

Format for Disclosures under Regulation 10(5) – Intimation to Stock Exchanges in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

1.	Name of the Target Company (TC)	Jagsonpal Pharmaceuticals Limited
2.	Name of the acquirer(s)	Infinity Portfolio Holdings
3.	Whether the acquirer(s) is/ are promoters of the TC prior to the transaction. If not, nature of relationship or association with the TC or its promoters	In accordance with the (Indian) Companies Act, 2013, (i) Infinity Portfolio Holdings (i.e. the acquirer) is a subsidiary of Infinity Investment Management; and (ii) Infinity Holdings and Infinity Consumer Holdings (which are both promoters and part of the promoter group of the TC) are also subsidiaries of Infinity Investment Management. Infinity Investment Management holds 100% voting rights in each of Infinity Portfolio Holdings, Infinity Holdings and Infinity Consumer Holdings.
4.	Details of the proposed acquisition	
	a. Name of the person(s) from whom shares are to be acquired	Infinity Holdings and Infinity Consumer Holdings
	b. Proposed date of acquisition	Any time after 4 working days from the date of this intimation
	c. Number of shares to be acquired from each person mentioned in 4(a) above	Infinity Holdings - 2,200,000 shares Infinity Consumer Holdings - 87,180 shares
	d. Total shares to be acquired as % of share capital of TC	8.6%
	e. Price at which shares are proposed to be acquired	The shares of TC will be acquired at a price not exceeding the limits provided in proviso (i) to Regulation 10(1)(a) of the SEBI SAST Regulations
	f. Rationale, if any, for the proposed transfer	Internal Restructuring
5.	Relevant sub-clause of regulation 10(1)(a) under which the acquirer is exempted from making open offer	Regulation 10(1)(a)(iii) of the SEBI SAST Regulations

6.	If, frequently traded, volume weighted average market price for a period of 60 trading days preceding the date of issuance of this notice as traded on the stock exchange where the maximum volume of trading in the shares of the TC are recorded during such period.	The shares of the TC are frequently traded in terms of Regulation 2(1)(j) of the SEBI SAST Regulations. The volume weighted average market price for a period of 60 trading days preceding the date of issuance of this notice as traded on the stock exchange where the maximum volume of trading in the shares of the TC are recorded during such period is Rs 365.19 per share.
----	--	--

7.	If in-frequently traded, the price as determined in terms of clause (e) of sub-regulation (2) of regulation 8.	Not applicable
8.	Declaration by the acquirer, that the acquisition price would not be higher by more than 25% of the price computed in point 6 or point 7 as applicable.	Attached as Annexure I
9.	Declaration by the acquirer, that the transferor and transferee have complied / will comply with applicable disclosure requirements in Chapter V of the Takeover Regulations, 2011 (corresponding provisions of the repealed Takeover Regulations 1997)	Attached as Annexure I
10.	Declaration by the acquirer that all the conditions specified under regulation 10(1)(a) with respect to exemptions has been duly complied with.	Attached as Annexure I

11.	Shareholding details		Before the proposed transaction		After the proposed transaction	
			No. of shares /voting rights	% w.r.t total share capital of TC	No. of shares /voting rights	% w.r.t total share capital of TC
	a	Acquirer(s) and PACs (other than sellers)				
		Infinity Portfolio Holdings	-	-	2,287,180	8.6%
		Infinity Holdings Sidecar I	4,755,300	18.0%	4,755,300	18.0%
	b	Seller (s)				
		Infinity Holdings	6,613,020	25.0%	4,413,020	16.7%
		Infinity Consumer Holdings	87,180	0.3%	-	-
	Total		11,455,500	43.3%	11,455,500	43.3%

Annexure-I

TO WHOMSOEVER IT MAY CONCERN

We hereby confirm the following with respect to the Proposed Transaction:

1. That the per share value of Jagsonpal Pharmaceuticals Ltd. taken into account for the acquisition price for the Proposed Transaction would not be higher by more than 25% of the price per share of Jagsonpal Pharmaceuticals Ltd. computed in accordance with Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
2. That we have complied / will comply with applicable disclosure requirements in Chapter V of the Takeover Regulations, 2011 (corresponding provisions of the repealed Takeover Regulations 1997)
3. All the conditions specified under regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 with respect to exemptions has been duly complied with.

For **Infinity Portfolio Holdings**



Kooshal Ashley Torul (Director)

Authorized signatory

Place: Mauritius

Date: September 05th 2024

Infinity Portfolio Holdings

C/o Apex Fund & Corporate Services (Mauritius)
Ltd, Lot 15 A3 1st Floor, Cybercity, Ebene 72201, Mauritius
Tel: +230 404 3900 Fax: +230 454 6824

Date: September 16th 2024

To

BSE Limited Phiroz Jeejeebhoy Towers, Dalal Street, Mumbai – 400001	National Stock Exchange of India Ltd., Exchange Plaza, C-1, Block G Bandra Kurla Complex Bandra East Mumbai 400051
--	---

CC: Jagsonpal Pharmaceuticals Ltd.

Registered Office:

T 210 J, Shabpur Jat,

New Delhi, Delhi-110049

Dear Sir/ Madam,

Re: Disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 on account of the acquisition of equity shares of Jagsonpal Pharmaceuticals Ltd (“Target Company”).

In compliance with the provisions of Regulation 10(1)(a)(iii) read with Regulation 10(6) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011, we wish to submit the disclosure with regard to the purchase of (i) 2,200,000 equity shares of Target Company by Infinity Portfolio Holdings from Infinity Holdings; and (ii) 87,180 equity shares of Target Company by Infinity Portfolio Holdings from Infinity Consumer Holdings, through on-market transactions.

Kindly acknowledge receipt of the same.

Thanking you,

Yours faithfully,

For Infinity Portfolio Holdings

Kooshal Ashley Torul (Director)

Authorized signatory

Place: Mauritius

Date: September 16th 2024

Format for Disclosures under Regulation 10(6) –Report to Stock Exchanges in respect of any acquisition made in reliance upon exemption provided for in Regulation 10 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

1.	Name of the Target Company (TC)	Jagsonpal Pharmaceuticals Limited	
2.	Name of the acquirer(s)	Infinity Portfolio Holdings	
3.	Name of the stock exchange where shares of the TC are listed	BSE and NSE	
4.	Details of the transaction including rationale, if any, for the transfer/acquisition of shares.	Internal Restructuring Details of the Acquisition – please see below	
5.	Relevant regulation under which the acquirer is exempted from making open offer.	Regulation 10(1)(a)(iii) of the SEBI SAST Regulations	
6.	Whether disclosure of proposed acquisition was required to be made under regulation 10 (5) and if so, - whether disclosure was made and whether it was made within the timeline specified under the regulations. - date of filing with the stock exchange.	Yes, the disclosure was required to be made under regulation 10(5) of the SEBI (SAST) Regulations. The said disclosure was filed within the specified timeline under the said regulations. The disclosure under Reg. 10(5) of SEBI (SAST) Regulations was filed on 5 th September 2024	
7.	Details of acquisition	Disclosures required to be made under regulation 10(5)	Whether the disclosures under regulation 10(5) are actually made
	a. Name of the transferor / seller	Infinity Holdings	Yes
		Infinity Consumer Holdings	Yes
	b. Date of acquisition	September 13 th 2024	Extract of Disclosure made under regulation 10(5): “Anytime after 4 working days from the date of intimation under regulation 10(5)”
	c. Number of shares/ voting rights in respect of the acquisitions from	Infinity Holdings – 2,200,000 equity shares	Yes

		each person mentioned in 7(a) above	Infinity Direct Holdings – 87,180 equity shares		
	d.	Total shares proposed to be acquired / actually acquired as a % of diluted share capital of TC	8.60%		Yes
	e.	Price at which shares are proposed to be acquired / actually acquired	2,200,000 shares at Rs. 400 per share 87,180 shares at Rs. 406.25 per share		Extract of Disclosure made under regulation 10(5): “The shares of TC will be acquired at a price not exceeding the limits provided in proviso (i) to Regulation 10(1)(a) of the SEBI SAST Regulations”
8.	Shareholding details		Pre-Transaction		Post-Transaction
			No. of shares held	% w.r.t total share capital of TC	No. of shares held % w.r.t total share capital of TC
	a	Each Acquirer / Transferee(*)			
		Infinity Portfolio Holdings	-	-	2,287,180 8.6%
	b	Each Seller / Transferor			
		Infinity Holdings	6,613,020	25.0%	4,413,020 16.7%
		Infinity Consumer Holdings	87,180	0.3%	- -
		Total	6,700,200	25.3%	6,700,200 25.3%

For Infinity Portfolio Holdings



Kooshal Ashley Torul (Director)

Authorized signatory

Place: Mauritius

Date: September 16th 2024

Infinity Portfolio Holdings

C/o Apex Fund & Corporate Services (Mauritius)
Ltd, Lot 15 A3 1st Floor, Cybercity, Ebene 72201, Mauritius
Tel: +230 404 3900 Fax: +230 454 6824

Date: September 17th 2024

To

BSE Limited Phiroz Jeejeebhoy Towers, Dalal Street, Mumbai – 400001	National Stock Exchange of India Ltd., Exchange Plaza, C-1, Block G Bandra Kurla Complex Bandra East Mumbai 400051
--	---

CC: Jagsonpal
Pharmaceuticals Ltd.
Registered Office:
T 210 J, Shabpur Jat,
New Delhi, Delhi-110049

Dear Sir/ Madam,

Re: Reporting of purchase of equity shares of Jagsonpal Pharmaceuticals Ltd (“Target Company”) under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

We wish to inform you that Infinity Portfolio Holdings acquired the following shares of the Target Company:

- (i) 2,200,000 equity shares of Target Company acquired by Infinity Portfolio Holdings from Infinity Holdings; and
- (ii) 87,180 equity shares of Target Company acquired by Infinity Portfolio Holdings from Infinity Consumer Holdings,

in each case through on-market transactions.

With regard to this, we hereby submit disclosure to Stock Exchanges under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Thanking you,

Yours faithfully,

For **Infinity Portfolio Holdings**

Kooshal Ashley Torul (Director)
Authorized signatory
Place: Mauritius
Date: September 17th 2024

ANNEXURE – 1

Format for disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011**PART- A - Details of the Acquisition**

Name of the Target Company (TC)		Jagsonpal Pharmaceuticals Ltd		
Name(s) of the acquirer and Persons Acting in Concert s(PAC) with the acquirer		Acquirer: Infinity Portfolio Holdings PAC: Infinity Holdings, Infinity Holdings Sidecar I Infinity Consumer Holdings		
Whether the acquirer belongs to Promoter/Promoter group		Yes		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed		National Stock Exchange of India Limited and BSE Limited		
Details of the acquisition as follows		Number	% w.r.t.total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
Sr No.	Before the acquisition under consideration, holding of:			
a)	Shares carrying voting rights:			
	i) Infinity Holdings	6,613,020	25.0%	25.0%
	ii) Infinity Holdings Sidecar I	4,755,300	18.0%	18.0%
	iii) Infinity Consumer Holdings	87,180	0.3%	0.3%
b)	Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	N/A	N/A	N/A
c)	Voting rights (VR) otherwise than by shares	N/A	N/A	N/A
d)	Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the T C (specify holding in each category)	N/A	N/A	N/A
e)	Total (a+b+c+d)	11,455,500	43.3%	43.3%
Sr No.	Details of acquisition/sale			
a)	Shares carrying voting rights sold			
	i) Infinity Holdings	(2,200,000)	(8.3%)	(8.3%)
	ii) Infinity Consumer Holdings	(87,180)	(0.3%)	(0.3%)
	Shares carrying voting rights acquired			
	iii) Infinity Portfolio Holdings	2,287,180	8.6%	8.6%
b)	VRs acquired /sold otherwise than by shares	N/A	N/A	N/A
c)	Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold	N/A	N/A	N/A
d)	Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	N/A	N/A	N/A
e)	Total (a+b+c+/-d)	-	-	-
Sr No.	After the acquisition / sale, holding of:			
a)	Shares carrying voting rights			
	i) Infinity Holdings	4,413,020	16.7%	16.7%
	ii) Infinity Holdings Sidecar I	4,755,300	18.0%	18.0%
	iii) Infinity Portfolio Holdings	2,287,180	8.6%	8.6%

b)	Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	N/A	N/A	N/A
c)	VRs otherwise than by shares	N/A	N/A	N/A
d)	Warrants/convertible securities/any other instrument-that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	N/A	N/A	N/A
e)	Total (a+b+c+d)	11,455,500	43.3%	43.3%
Mode of sale (e.g. open market / public issue / rights issue / preferential allotment / inter-se transfer / encumbrance, etc.)		On market Transaction		
Date of sale of shares / date of receipt of intimation of allotment of shares / VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC.		September 13 th 2024		
Equity share capital / total voting capital of the TC before the said acquisition/sale		Rs. 132,285,555 consisting of 2,64,57,111 equity shares of Rs. 5 each		
Equity share capital / total voting capital of the TC after the said acquisition/sale		Rs. 132,285,555 consisting of 2,64,57,111 equity shares of Rs. 5 each		
Total diluted share/voting capital of the TC after the said acquisition/sale		Rs. 132,285,555 consisting of 2,64,57,111 equity shares of Rs. 5 each		

Infinity Holdings

C/o Apex Fund & Corporate Services (Mauritius)
 Ltd, Lot 15 A3 1st Floor, Cybercity, Ebene 72201, Mauritius
 Tel: +230 404 3900 Fax: +230 454 6824

Date: September 17th 2024

To

BSE Limited Phiroz Jeejeebhoy Towers, Dalal Street, Mumbai – 400001	National Stock Exchange of India Ltd., Exchange Plaza, C-1, Block G Bandra Kurla Complex Bandra East Mumbai 400051
--	---

CC: **Jagsonpal**
Pharmaceuticals Ltd.
 Registered Office:
 T 210 J, Shabpur Jat,
 New Delhi, Delhi-110049

Dear Sir/ Madam,

Re: Reporting of sale of equity shares of Jagsonpal Pharmaceuticals Ltd (“Target Company”) under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

We wish to inform you that:

- (i) Infinity Holdings has sold 2,200,000 equity shares of Target Company to Infinity Portfolio Holdings, through on-market transaction.
- (ii) Infinity Consumer Holdings has sold 87,180 equity shares of Target Company to Infinity Portfolio Holdings, through on-market transaction.

With regard to this, we hereby submit disclosure to Stock Exchanges under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Thanking you,

Yours faithfully,

For **Infinity Holdings**



Mohammud Zaid Peerun (Director)
 Authorized signatory
 Place: Mauritius
 Date: September 17th 2024

For **Infinity Consumer Holdings**



Mahmade Rehza Hassen Auliar (Director)
 Authorized signatory
 Place: Mauritius
 Date: September 17th 2024

ANNEXURE – 1

Format for disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)		Jagsonpal Pharmaceuticals Ltd		
Name(s) of the seller and Persons Acting in Concert (PAC) with the seller		Seller: Infinity Holdings, Infinity Consumer Holdings		
		PAC: Infinity Portfolio Holdings, Infinity Holdings Sidecar I		
Whether the seller belongs to Promoter/Promoter group		Yes		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed		National Stock Exchange of India Limited and BSE Limited		
Details of the acquisition as follows		Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
Sr No.	Before the acquisition under consideration, holding of:			
a)	Shares carrying voting rights:			
	i) Infinity Holdings	6,613,020	25.0%	25.0%
	ii) Infinity Holdings Sidecar I	4,755,300	18.0%	18.0%
	iii) Infinity Consumer Holdings	87,180	0.3%	0.3%
b)	Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	N/A	N/A	N/A
c)	Voting rights (VR) otherwise than by shares	N/A	N/A	N/A
d)	Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the T C (specify holding in each category)	N/A	N/A	N/A
e)	Total (a+b+c+d)	11,455,500	43.3%	43.3%
Sr No.	Details of acquisition/sale			
a)	Shares carrying voting rights sold			
	i) Infinity Holdings	(2,200,000)	(8.3%)	(8.3%)
	ii) Infinity Consumer Holdings	(87,180)	(0.3%)	(0.3%)
	Shares carrying voting rights acquired			
	iii) Infinity Portfolio Holdings	2,287,180	8.6%	8.6%
b)	VRs acquired /sold otherwise than by shares	N/A	N/A	N/A
c)	Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold	N/A	N/A	N/A
d)	Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	N/A	N/A	N/A
e)	Total (a+b+c+/-d)	-	-	-
Sr No.	After the acquisition / sale, holding of:			
a)	Shares carrying voting rights			
	i) Infinity Holdings	4,413,020	16.7%	16.7%
	ii) Infinity Holdings Sidecar I	4,755,300	18.0%	18.0%
	iii) Infinity Portfolio Holdings	2,287,180	8.6%	8.6%

b)	Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	N/A	N/A	N/A
c)	VRs otherwise than by shares	N/A	N/A	N/A
d)	Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	N/A	N/A	N/A
e)	Total (a+b+c+d)	11,455,500	43.3%	43.3%
Mode of sale (e.g. open market / public issue / rights issue / preferential allotment / inter-se transfer / encumbrance, etc.)		On market Transaction		
Date of sale of shares / date of receipt of intimation of allotment of shares / VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC.		September 13 th 2024		
Equity share capital / total voting capital of the TC before the said acquisition/sale		Rs. 132,285,555 consisting of 2,64,57,111 equity shares of Rs. 5 each		
Equity share capital / total voting capital of the TC after the said acquisition/sale		Rs. 132,285,555 consisting of 2,64,57,111 equity shares of Rs. 5 each		
Total diluted share/voting capital of the TC after the said acquisition/sale		Rs. 132,285,555 consisting of 2,64,57,111 equity shares of Rs. 5 each		

Signature of Authorised Signatory**Infinity Holdings**


Mohammud Zaid Peerun (Director)
Authorised Signatory

Place: Mauritius

Date: September 17th 2024

Infinity Consumer Holdings


Mahmade Rehza Hassen Auliar (Director)
Authorised Signatory

Place: Mauritius

Date: September 17th 2024